Dec2021

Retrospective Analysis – The way forward for RBQM in the world of ICH E6(R3)

December 8, 2021|Comments Off on Retrospective Analysis – The way forward for RBQM in the world of ICH E6(R3)

We recently sat down with Halloran Consulting Group, Inc. at their CORE event, discussing the value of taking a retrospective analysis approach to RBQM implementation. The discussion was very well received and provided significant insight into the upcoming ICH E6(R3) guidelines, which will provide clarity on RBM and RBQM implementation within the clinical research space. Read through our discussion here.

Mar2021

4 Ways to Optimize Vaccine Trials in Coronavirus Variants

March 15, 2021|Comments Off on 4 Ways to Optimize Vaccine Trials in Coronavirus Variants

Learn how risk-based quality management (RBQM) helps simplify coronavirus vaccine development and helps mitigate any unnecessary burden from clinical organizations ensuring vaccines are readily available when needed.

May2020

Machine Learning-Based Predictions for All Clinical Research Metrics

May 27, 2020|Comments Off on Machine Learning-Based Predictions for All Clinical Research Metrics

MyRBQM® Portal's new Machine Learning predictive analytics model is far less sensitive to noise, it better generalizes data, and provides narrower CIs in long time series. Singular Spectrum Analysis is particularly valuable for long time series, as mostly observed in clinical trials.

Mar2020

Cyntegrity Amongst Companies Fighting Back the COVID-19 Outbreak

March 23, 2020|Comments Off on Cyntegrity Amongst Companies Fighting Back the COVID-19 Outbreak

Frontiers Health Ecosystem Companies Fighting Back the COVID-19 Outbreak As the COVID-19 outbreak continues, it has become even more challenging for patients to seek in- person medical care and for healthcare providers (HCP) to [...]

Mar2020

Coronavirus | COVID-19 RACT Now Available

March 20, 2020|Comments Off on Coronavirus | COVID-19 RACT Now Available

Cyntegrity developed a special COVID-19 RACT that guides those involved in clinical trials on specific risks which may arise as a result of COVID-19, and how they can mitigate them. This special RACT is part of the COVID-19 rapid deployment pack for ad-hoc centralized monitoring.